‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban

Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and Cassava, the FTC alleges.